基于CT的影像组学列线图预测小细胞肺癌无进展生存期:一项多中心队列研究
研究回顾性纳入三个医疗中心558例病理确诊小细胞肺癌患者,基于6个CT影像组学特征构建影像组学列线图预测无进展生存期。影像组学标签与无进展生存期显著相关(HR 4.531,95%CI 3.524-5.825,p<0.001),影像组学列线图C指数0.799优于临床列线图0.629,6个月和12个月AUC分别为0.885和0.846,净重分类改善33.7%、综合判别改善22.7%,决策曲线分析显示其临床实用性优于临床列线图。
要点
- 共筛选出6个CT影像组学特征,影像组学标签与无进展生存期显著相关(HR 4.531,95%CI 3.524-5.825,p<0.001)。
- 影像组学列线图预测无进展生存期的C指数为0.799,优于临床列线图的0.629。
- 影像组线图6个月和12个月AUC分别为0.885和0.846,净重分类改善33.7%,综合判别改善22.7%。
核心结论
- 基于CT的影像组学列线图在预测小细胞肺癌患者无进展生存期方面表现出良好性能,可为个体化治疗提供有价值的信息。
研究设计与样本
- 回顾性多中心队列研究,从三个医疗中心纳入558例病理确诊的小细胞肺癌患者,基于CT构建影像组学标签并开发列线图。
诊断标准与关键数值
- 影像组学标签与无进展生存期显著相关(HR 4.531,95%CI 3.524-5.825,p<0.001)。
- 影像组学列线图预测无进展生存期的C指数为0.799,临床列线图C指数为0.629。
- 影像组学列线图6个月和12个月AUC分别为0.885和0.846。
- 净重分类改善33.7%(95%CI 0.216-0.609,p<0.05),综合判别改善22.7%(95%CI 0.168-0.278,p<0.05)。
临床应用与阅片要点
- 作者认为,基于CT的影像组学列线图预测小细胞肺癌无进展生存期表现出良好性能,可为个体化治疗提供有价值的信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To develop a radiomics nomogram based on computed tomography (CT) to estimate progression-free survival (PFS) in patients with small cell lung cancer (SCLC) and assess its incremental value to the clinical risk factors for individual PFS estimation.
METHODS: 558 patients with pathologically confirmed SCLC were retrospectively recruited from three medical centers. A radiomics signature was generated by using the Pearson correlation analysis, univariate Cox analysis, and multivariate Cox analysis. Association of the radiomics signature with PFS was evaluated. A radiomics nomogram was developed based on the radiomics signature, then its calibration, discrimination, reclassification, and clinical usefulness were evaluated.
RESULTS: In total, 6 CT radiomics features were finally selected. The radiomics signature was significantly associated with PFS (hazard ratio [HR] 4.531, 95% confidence interval [CI] 3.524-5.825, p < 0.001). Incorporating the radiomics signature into the radiomics nomogram resulted in better performance for the estimation of PFS (concordance index [C-index] 0.799) than with the clinical nomogram (C-index 0.629), as well as high 6 months and 12 months area under the curves of 0.885 and 0.846, respectively. Furthermore, the radiomics nomogram also significantly improved the classification accuracy for PFS outcomes, based on the net reclassification improvement (33.7%, 95% CI 0.216-0.609, p < 0.05) and integrated discrimination improvement (22.7%, 95% CI 0.168-0.278, p < 0.05). Decision curve analysis demonstrated that in terms of clinical usefulness, the radiomics nomogram outperformed the clinical nomogram.
CONCLUSION: A CT-based radiomics nomogram exhibited a promising performance for predicting PFS in patients with SCLC, which could provide valuable information for individualized treatment.
引用
- Zheng X, Liu K, Li C, et al. A CT-based radiomics nomogram for predicting the progression-free survival in small cell lung cancer: a multicenter cohort study. Radiol Med. 2023. PMID: 37597124. doi:10.1007/s11547-023-01702-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。